Zhong-Qi Bian

Zhong-Qi Bian

Auto-generated profile, based on publicly available information

Zhong-Qi Bian

Center for Infectious Diseases, Kunming General Hospital, PLA, Kunming 650032, China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2012 in Molecules
Verified
Journal Article
Open access
PDF file
GZGuo-Ying Zuo
Guo-Ying Zuo
YLYang Li
Yang Li
JHJun Han
Jun Han
GWGen-Chun Wang
Gen-Chun Wang
YZYun-Ling Zhang
Yun-Ling Zhang
ZBZhong-Qi Bian
Zhong-Qi Bian
Antibacterial activity of berberine (Ber) and 8-acetonyl-dihydroberberine (A-Ber) alone and combined uses with antibacterial agents ampicillin (AMP), azithromycin (AZM), cefazolin (CFZ) and levofloxacin (LEV) was studied on 10 clinical isolates of SCCmec III type methicillin-resistant Staphylococcus aureus (MRSA). Susceptibility to each agent alone was tested using a broth microdilution method and the chequerboard and time-kill tests for the combined evaluations, respectively. The alone MICs/MBCs (mg/mL) ranges were 32–128/64–256 (Ber) and 32-128/128-512 (A-Ber). Significant synergies were observed for the Ber (A-Ber)/AZM and Ber (A-Ber)/LEV combinations against 90% of the tested MRSA strains, with fractional inhibitory concentration indices (FICIs) values ranged from 0.188 to 0.500. An additivity result was also observed for the Ber/AZM combination by time-kill curves. These results demonstrated for the first time that Ber and A-Ber enhanced the in vitro inhibitory efficacy of AZM and LEV to a same extent, which had potential for further investigation in combinatory therapeutic applications of patients infected with MRSA.

9 March 2012 in Molecules
Verified
Journal Article
Open access
PDF file
GZGuo-Ying Zuo
Guo-Ying Zuo
XZXin-Juan Zhang
Xin-Juan Zhang
CYCui-Xian Yang
Cui-Xian Yang
JHJun Han
Jun Han
GWGen-Chun Wang
Gen-Chun Wang
ZBZhong-Qi Bian
Zhong-Qi Bian
The in vitro antimicrobial activities of 30 Chinese medicinal plants were evaluated with reference to the treatment record of infectious diseases in the Traditional Chinese Medicine (TCM) literature. The plant materials were extracted with 80% ethanol and the extracts were primarily screened against conventional clinical pathogens like Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Candida albicans by the agar diffusion method. Their inhibition zone diameters (IZDs, mm, 50 mg/mL) ranged from 2,048 by the standard broth microdilution method. The seven extracts from M. yunnanensis, S. sinensis, G. morella, E. daneillii, M. squamulata, S. arborescens and B. hancei were determined as the most active extracts, with MICs of 8–64 μg/mL. The results were in good agreement with their traditional applications in skin and other infections.

Verified
Journal Article
Open access
PDF file
GZGuo-Ying Zuo
Guo-Ying Zuo
JAJing An
Jing An
JHJun Han
Jun Han
YZYun-Ling Zhang
Yun-Ling Zhang
GWGen-Chun Wang
Gen-Chun Wang
ZBZhong-Qi Bian
Zhong-Qi Bian
Through bioassay-guided fractionation of the extracts from the aerial parts of the Chinese herb Hypericum japonicum Thunb. Murray, Isojacareubin (ISJ) was characterized as a potent antibacterial compound against the clinical methicillin-resistant Staphylococcus aureus (MRSA). The broth microdilution assay was used to determine the minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) of ISJ alone. The results showed that its MICs/MBCs ranged from 4/16 to 16/64 μg/mL, with the concentrations required to inhibit or kill 50% of the strains (MIC50/MBC50) at 8/16 μg/mL. Synergistic evaluations of this compound with four conventional antibacterial agents representing different types were performed by the chequerboard and time-kill tests. The chequerboard method showed significant synergy effects when ISJ was combined with Ceftazidime (CAZ), Levofloxacin (LEV) and Ampicillin (AMP), with the values of 50% of the fractional inhibitory concentration indices (FICI50) at 0.25, 0.37 and 0.37, respectively. Combined bactericidal activities were also observed in the time-kill dynamic assay. The results showed the ability of ISJ to reduce MRSA viable counts by log10CFU/mL at 24 h of incubation at a concentration of 1 × MIC were 1.5 (LEV, additivity), 0.92 (CAZ, indifference) and 0.82 (AMP, indifference), respectively. These in vitro anti-MRSA activities of ISJ alone and its synergy with conventional antibacterial agents demonstrated that ISJ enhanced their efficacy, which is of potential use for single and combinatory therapy of patients infected with MRSA.

14 March 2006
Verified
Journal Article
Closed access
ZBZhong-Qi Bian
Zhong-Qi Bian
ZHZhan-Lou Hua
Zhan-Lou Hua
WYWei-Yao Yan
Wei-Yao Yan
MLMing-Qiu Liu
Ming-Qiu Liu
DWDian-Yuan Wu
Dian-Yuan Wu
ZZZhao-Xin Zheng
Zhao-Xin Zheng

11 April 2006
Verified
Journal Article
Closed access
ZBZhong-Qi Bian
Zhong-Qi Bian
ZHZhan-Lou Hua
Zhan-Lou Hua
WYWei-Yao Yan
Wei-Yao Yan
MLMing-Qiu Liu
Ming-Qiu Liu
ZZZhao-Xin Zheng
Zhao-Xin Zheng